loading
前日終値:
$52.53
開ける:
$52.55
24時間の取引高:
21.28M
Relative Volume:
9.86
時価総額:
$6.63B
収益:
$947.36M
当期純損益:
$392.47M
株価収益率:
17.29
EPS:
3.02
ネットキャッシュフロー:
$392.71M
1週間 パフォーマンス:
-1.14%
1か月 パフォーマンス:
-4.06%
6か月 パフォーマンス:
+8.48%
1年 パフォーマンス:
+1.12%
1日の値動き範囲:
Value
$51.93
$53.00
1週間の範囲:
Value
$51.89
$54.13
52週間の値動き範囲:
Value
$42.01
$70.50

Halozyme Therapeutics Inc Stock (HALO) Company Profile

Name
名前
Halozyme Therapeutics Inc
Name
セクター
Healthcare (1174)
Name
電話
(858) 794-8889
Name
住所
12390 EL CAMINO REAL, SAN DIEGO, CA
Name
職員
350
Name
Twitter
@halozymeinc
Name
次回の収益日
2025-02-18
Name
最新のSEC提出書
Name
HALO's Discussions on Twitter

HALO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
HALO
Halozyme Therapeutics Inc
52.21 6.63B 947.36M 392.47M 392.71M 3.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-05-14 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-05-13 ダウングレード Leerink Partners Market Perform → Underperform
2024-10-07 ダウングレード Wells Fargo Overweight → Equal Weight
2024-09-19 ダウングレード JP Morgan Overweight → Neutral
2024-06-07 ダウングレード Piper Sandler Overweight → Neutral
2024-02-29 開始されました TD Cowen Outperform
2023-07-24 ダウングレード Goldman Buy → Neutral
2023-07-24 開始されました H.C. Wainwright Buy
2023-05-10 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Berenberg Buy
2023-03-16 ダウングレード SVB Securities Outperform → Market Perform
2022-12-21 再開されました Morgan Stanley Overweight
2022-11-28 開始されました Wells Fargo Overweight
2022-09-09 開始されました Morgan Stanley Overweight
2022-05-23 開始されました SVB Leerink Outperform
2021-06-14 開始されました Evercore ISI Outperform
2021-05-17 開始されました SVB Leerink Outperform
2021-05-11 ダウングレード Piper Sandler Overweight → Neutral
2021-01-21 繰り返されました The Benchmark Company Buy
2020-12-17 開始されました Berenberg Buy
2020-09-14 再開されました JP Morgan Overweight
2020-07-01 開始されました The Benchmark Company Buy
2020-02-05 アップグレード Piper Sandler Neutral → Overweight
2020-01-09 アップグレード BMO Capital Markets Market Perform → Outperform
2020-01-08 開始されました Goldman Buy
2019-11-05 アップグレード Barclays Underweight → Equal Weight
2018-10-19 再開されました Piper Jaffray Neutral
2018-05-11 ダウングレード Barclays Equal Weight → Underweight
2018-01-24 開始されました Goldman Neutral
2017-10-16 繰り返されました Piper Jaffray Overweight
2017-01-06 ダウングレード Citigroup Buy → Neutral
2016-11-03 開始されました Deutsche Bank Buy
2015-12-04 開始されました Wells Fargo Outperform
2015-11-18 開始されました Citigroup Buy
2015-09-22 開始されました Barclays Overweight
2015-06-22 繰り返されました JP Morgan Overweight
2015-03-03 繰り返されました UBS Buy
2015-02-18 繰り返されました MLV & Co Buy
2015-01-08 繰り返されました MLV & Co Buy
すべてを表示

Halozyme Therapeutics Inc (HALO) 最新ニュース

pulisher
Jun 18, 2025

Therapeutics (NASDAQ:HALO) Stock Nasdaq Composite - Kalkine Media

Jun 18, 2025
pulisher
Jun 18, 2025

Investors in Halozyme Therapeutics (NASDAQ:HALO) have seen impressive returns of 107% over the past five years - simplywall.st

Jun 18, 2025
pulisher
Jun 16, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance

Jun 16, 2025
pulisher
Jun 15, 2025

Halozyme Therapeutics: The Waters Become Muddled (NASDAQ:HALO) - Seeking Alpha

Jun 15, 2025
pulisher
Jun 13, 2025

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance

Jun 13, 2025
pulisher
Jun 12, 2025

Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - MSN

Jun 11, 2025
pulisher
Jun 10, 2025

TD Cowen reiterates buy rating on Halozyme stock amid CMS impact analysis - Investing.com Canada

Jun 10, 2025
pulisher
Jun 09, 2025

Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth By Investing.com - Investing.com Nigeria

Jun 09, 2025
pulisher
Jun 09, 2025

Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 06, 2025

Merck gains U.S. patent office support in Keytruda dispute - MSN

Jun 06, 2025
pulisher
Jun 05, 2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com

Jun 05, 2025
pulisher
Jun 05, 2025

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

Merck (MRK) Gains Edge in Keytruda Patent Dispute - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Merck dispute with Halozyme over Keytruda injection to get another USPTO look - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Merck granted review of Halozyme patent claims by PTAB - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme - Yahoo Finance

Jun 04, 2025
pulisher
Jun 03, 2025

Halozyme (HALO) Faces Patent Challenge as USPTO Institutes Revie - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Halozyme (HALO) Faces Patent Challenges Affecting Stock Outlook - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Here’s Why Halozyme Therapeutics (HALO) Rebounded in Q1 - Insider Monkey

Jun 03, 2025
pulisher
Jun 02, 2025

(HALO) Investment Report - news.stocktradersdaily.com

Jun 02, 2025
pulisher
May 30, 2025

Halozyme to Participate at Upcoming Investor Conferences - Kilgore News Herald

May 30, 2025
pulisher
May 30, 2025

Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright - Defense World

May 30, 2025
pulisher
May 29, 2025

Halozyme Therapeutics (HALO): HC Wainwright & Co. Reiterates Buy Rating | HALO Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Longview News-Journal

May 29, 2025
pulisher
May 29, 2025

Halozyme stock holds Buy rating, $72 target from H.C. Wainwright By Investing.com - Investing.com UK

May 29, 2025
pulisher
May 28, 2025

Halozyme to Participate at Upcoming Investor Conferences | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Halozyme CEO Sets Two Major Healthcare Conference Appearances: Goldman Sachs and Benchmark - Stock Titan

May 28, 2025
pulisher
May 28, 2025

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) - sharewise

May 28, 2025
pulisher
May 28, 2025

Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme - MSN

May 28, 2025
pulisher
May 28, 2025

Implied Volatility Surging for Halozyme Therapeutics Stock Options - The Globe and Mail

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE - Nasdaq

May 28, 2025
pulisher
May 28, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Breakthrough: EU Approves 5-Minute Cancer Treatment Option Using Halozyme's Technology - Stock Titan

May 28, 2025
pulisher
May 28, 2025

High Growth Tech Stocks To Watch In The US May 2025 - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

New Strong Buy Stocks for May 28th - The Globe and Mail

May 28, 2025
pulisher
May 18, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Hold” by Brokerages - Defense World

May 18, 2025
pulisher
May 16, 2025

J&J, Halozyme cut at Leerink on price control risk for combo products - MSN

May 16, 2025
pulisher
May 16, 2025

Halozyme Therapeutics (NASDAQ:HALO) Cut to “Strong Sell” at Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 15, 2025

Halozyme downgraded at Morgan Stanley on price control risk - MSN

May 15, 2025
pulisher
May 15, 2025

Morgan Stanley Downgrades Halozyme Therapeutics (BIT:1HALO) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Morgan Stanley Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Leerink Partners Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Underperform - Defense World

May 15, 2025

Halozyme Therapeutics Inc (HALO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Halozyme Therapeutics Inc (HALO) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Torley Helen
PRESIDENT AND CEO
Jun 24 '25
Option Exercise
8.11
20,000
162,200
753,719
Torley Helen
PRESIDENT AND CEO
Jun 23 '25
Option Exercise
8.11
20,000
162,200
753,719
Torley Helen
PRESIDENT AND CEO
Jun 24 '25
Sale
53.73
20,000
1,074,620
733,719
Torley Helen
PRESIDENT AND CEO
Jun 20 '25
Sale
52.96
20,000
1,059,200
733,719
Torley Helen
PRESIDENT AND CEO
Jun 23 '25
Sale
52.57
20,000
1,051,460
733,719
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
大文字化:     |  ボリューム (24 時間):